The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1581
September 23, 2019
View Complete Issue         Table of Contents 2019 
Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
September 23, 2019 (Issue: 1581)
The FDA has approved glucagon nasal powder (Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become available in the US. Injectable...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
Article code: 1581b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.